GlassScriptPhysician profile
Alex M Su
NPI 1609871706
$22,675.10
in general payments reported to CMS, 2019-2025
72 companies · $2,886 in 2025
The $2,886 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,597 · 2020: $2,175 · 2021: $4,520 · 2022: $3,223 · 2023: $4,085 · 2024: $3,189 · 2025: $2,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,290 · Consulting Fee: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,290.42 |
| Consulting Fee | $870.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,359.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,481.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,857.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $1,363.12 | 2021 | |
| Abbvie INC. | $1,249.20 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,179.70 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $968.40 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $932.08 | 2019-2023 | |
| Glaxosmithkline, LLC. | $701.97 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $690.68 | 2019-2025 | Belsomra, Steglatro, Steglujan |
| Amgen INC. | $592.87 | 2020-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.95 | 2019-2025 | Xifaxan |
| Corium, LLC | $448.27 | 2022-2025 | Azstarys, Azstarys |
| Astellas Pharma US INC | $417.38 | 2019-2024 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $372.18 | 2019-2021 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.